PremiumThe FlyBayer sees FY25 sales EUR 46B-EUR 48B on currency-adjusted basis Bayer establishes additional provisions around EUR 1.2B for Roundup litigation Bayer ‘making headway’ on improving profitability in agricultural business PremiumThe FlyBayer’s emodepside granted FDA orphan designation Bayer AG Management Engages in Share Purchase to Boost Stakeholder Confidence RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study PremiumThe FlyBayer upgraded to Buy from Neutral at Goldman Sachs Bayer price target raised to EUR 28 from EUR 26 at Morgan Stanley Bayer says FDA accepts NDA under priority review for sevabertinib 
